Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
Recruiting · NCT05517811 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Colorado, Denver
View the official record on ClinicalTrials.gov →Interventions studied
TEG indices
What this trial is about
The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with virulent tumor biology.
Who can take part
Age range
18 Years to 99 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal, lung adenocarcinoma, or liver metastasis of any origin will be eligible for enrollment in the study
- 18 Years and older
Exclusion criteria
- Under 18 years old
- prisoners
- unable to provide informed consent
- pregnant women
- and those undergoing emergent or urgent operative intervention at the time of diagnosis
Where it is running
4 locations listed across 1 US state.
- University of Colorado Denver - Aurora, Colorado, United States
- University of Colorado Denver - Aurora, Colorado, United States
- UCHealth Highlands Ranch Hospital - Highlands Ranch, Colorado, United States
- UCHealth Highlands Ranch Hospital - Highlands Ranch, Colorado, United States